• +1-646-491-9876
    • +91-20-67278686

    Search

    Ependymoma - Pipeline Review, H1 2017

    Ependymoma - Pipeline Review, H1 2017

    • Report Code ID: RW0001709423
    • Category Pharmaceuticals
    • No. of Pages 53
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Ependymoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ependymoma - Pipeline Review, H1 2017, provides an overview of the Ependymoma (Oncology) pipeline landscape.

    Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of the cerebral spinal fluid (CSF) , causing increased intracranial pressure. Ependymomas are often slow growing tumours, and any signs and symptoms usually develop slowly over many months. The treatment for an ependymoma depends on a number of things, including your general health, the size and position of the tumour, and whether it has spread to other parts of the brain or spinal cord.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Ependymoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ependymoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Ependymoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ependymoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 2 and 3 respectively.

    Ependymoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Ependymoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Ependymoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Ependymoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Ependymoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Ependymoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Ependymoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Ependymoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Ependymoma - Overview
    Ependymoma - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Ependymoma - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Ependymoma - Companies Involved in Therapeutics Development
    Advantagene Inc
    Boehringer Ingelheim GmbH
    Cavion LLC
    Millennium Pharmaceuticals Inc
    NewLink Genetics Corp
    Ependymoma - Drug Profiles
    afatinib dimaleate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    alisertib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GliAtak - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    indoximod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mibefradil dihydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Ependymoma - Dormant Projects
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Ependymoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Ependymoma - Pipeline by Advantagene Inc, H1 2017
    Ependymoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Ependymoma - Pipeline by Cavion LLC, H1 2017
    Ependymoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Ependymoma - Pipeline by NewLink Genetics Corp, H1 2017
    Ependymoma - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Ependymoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Advantagene Inc
    Boehringer Ingelheim GmbH
    Cavion LLC
    Millennium Pharmaceuticals Inc
    NewLink Genetics Corp

    Request for Sample

    Report Url http://www.reportsweb.com//ependymoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//ependymoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//ependymoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments